Document:

Exhibit 10.2 First Amendment to Securities Purchase Agreement

EXHIBIT 10.2

FIRST AMENDMENT TO
SECURITIES PURCHASE AGREEMENT
This First Amendment to Securities Purchase Agreement, dated as of March 16, 2015 (this “Amendment”), is entered into by and between Summit Financial Group, Inc., a West Virginia corporation (the “Company”), and Castle Creek Capital Partners V, LP, a Delaware limited partnership (the “Investor”).
RECITALS:
A.    The Company and Investor entered into that certain Securities Purchase Agreement (the “Agreement”) on August 22, 2014 whereby Company agreed to sell to Investor, and Investor agreed to purchase from the Company, the securities described therein. 
B.    The parties seek to amend the Agreement to bring it into alignment with certain commitments made by the Company, Investor and certain of Investor’s Affiliates in the Passivity Commitments and Anti-Association Representations of Castle Creek Partners V, LP Relating to Summit Financial Group, Inc. delivered to the Board of Governors of the Federal Reserve System.
C.    The parties seek to address certain provisions in the Agreement that are triggered by the Company’s recent declaration of a common stock dividend. 
NOW, THEREFORE, in consideration of the premises and mutual promises set forth herein, the parties, intending to be legally bound, agree as follows:
1.Definitions.  For the purposes of this Amendment, all capitalized terms used in this Amendment that are not defined herein shall have the meanings ascribed to such terms in the Agreement.

2.Amendment.  Section 5.8(a) of the Agreement is hereby deleted in its entirety and replaced with the following: 

“(a)    Notwithstanding anything to the contrary in this Agreement, neither the Company nor any Company Subsidiary shall take any action (including any redemption, repurchase, or recapitalization of Common Stock, or securities or rights, options or warrants to purchase Common Stock, or securities of any type whatsoever that are, or may become, convertible into or exchangeable into or exercisable for Common Stock in each case, where the Investor is not given the right to participate in such redemption, repurchase or recapitalization to the extent of the Investor’s pro rata proportion), that would reasonably be expected to pose a substantial risk that the Investor’s ownership of any class of Voting securities of the Company (together with the ownership by Investor’s Affiliates (as such term is used under the BHC Act) of Voting securities of the Company) would exceed 9.99% of such class after the First Closing Date or the Second Closing Date, in each case without the prior written consent of Investor or such person, or to increase to an amount that would constitute “control” under the BHC Act, the Change of Bank Control Act of 1978, as amended (the “CBCA”) or any rules or regulations promulgated thereunder (or any successor provisions) or otherwise cause Investor to “control” the Company under and for purposes of the BHC Act, the CBCA or any rules 

1

or regulations promulgated thereunder (or any successor provisions). In the event the Company breaches its obligations under this Section 5.8(a) or believes that it is reasonably likely to breach such an obligation, it shall promptly notify the other parties hereto and shall cooperate in good faith with such parties to modify ownership or make other arrangements or take any other action, in each case, as is necessary to cure or avoid such breach.”
3.Second Closing Payment.  On February 26, 2015, the Company’s board of directors declared a dividend payable to its common shareholders in an amount equal to $0.08 per share and set a record date of March 16, 2015 (the “Declared Record Date”) for such dividend.  The Declared Record Date is prior to the Second Closing Date and in order to comply with Section 5.4(b) of the Agreement, the Company has agreed to reduce the cash proceeds that must be delivered by the Investor to the Company for the purchase of the Common Stock at the Second Closing (the “Second Closing Shares”) to reflect the necessary adjustment contemplated in the Agreement for the deemed dividend to Investor with respect to the Second Closing Shares, which amounts to $19,020.24.  The Purchase Price will not be adjusted.  At the Second Closing, Investor will deliver a cash amount to the Company in the amount of $2,299,071.51.

4.Enforceable Documents.  Except as modified herein, the parties agree that all terms and conditions of the Agreement are and shall remain in full force and effect.  

5.Severability.  If any provision of this Amendment is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Amendment will remain in full force and effect. Any provision of this Amendment held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable.

6.Applicable Law.  This Amendment shall be governed by, construed and enforced in accordance with the laws of the State of Delaware, without regard to the conflicts of laws principles.

7.Counterparts.  This Amendment may be executed in one or more counterparts, each of which will be deemed to be an original copy of this Amendment and all of which, when taken together, will be deemed to constitute one and the same agreement. The exchange of copies of this Amendment and of signature pages by facsimile or electronic transmission shall constitute effective execution and delivery of this Amendment as to the parties and may be used in lieu of the original Amendment for all purposes.  Signatures of the parties transmitted by facsimile or electronically shall be deemed to be their original signatures for all purposes.

2

IN WITNESS WHEREOF, this Amendment has been duly executed and delivered by the duly authorized officers of the parties hereto as of the date first herein above written.  

	
					
	 
	 
	SUMMIT FINANCIAL GROUP, INC.

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	 
	 
	By:    /s/  H. Charles Maddy, III

	 
	 
	Name:    H. Charles Maddy, III

	 
	 
	Title:    President and Chief Executive Officer

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	 
	 
	CASTLE CREEK CAPITAL PARTNERS V, LP

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	 
	 
	By:    /s/  David Volk

	 
	 
	Name:    David Volk

	 
	 
	Title:    Principal

3EXHIBIT 10.1

 

 

PATENT LICENSE AGREEMENT

(UTEP AND PREMIER BIOMEDICAL, INC.)

 

This Patent License Agreement is between the Licensor and the Licensee identified below (collectively, “Parties”, or singly, “Party”).

 

No binding agreement between the Parties regarding a Patent License will exist until this Patent License Agreement has been signed by both Parties. Unsigned drafts of this Patent License Agreement shall not be considered offers.

 

Background

 

Licensor owns or controls Patent Rights. Licensee desires to secure the right and license to use, develop, manufacture, market, and commercialize the Patent Rights. Licensor has determined that such use, development, and commercialization of the Patent Rights is in the public’s best interest and is consistent with Licensor’s educational and research missions and goals. Licensor desires to have the Patent Rights developed and used for the benefit of Licensee, the inventors, Licensor, and the public.

 

The parties entered a Collaborative Agreement (Collaborative Agreement) effective May 1, 2012 for the purpose of further developing the technology within the Field (as defined therein) which is the foundation agreement for this Patent License Agreement.

 

NOW, THEREFORE, in consideration of the mutual covenants and premises herein contained, the Parties hereby agree as follows:

 

The Terms and Conditions of Patent License attached hereto as Exhibit A are incorporated herein by reference in their entirety (the “Terms and Conditions”). In the event of a conflict between provisions of this Patent License Agreement and the Terms and Conditions, the provisions in this Patent License Agreement shall govern. Unless defined in this Patent License Agreement, capitalized terms used in this Patent License Agreement shall have the meanings given to them in the Terms and Conditions.

 

	 
	
1

	

 

The section numbers used in the left hand column in the table below correspond to the section numbers in the Terms and Conditions.

 

	
1.  Definitions

 

	
 

	
Effective Date

	
February 20, 2015

	
 

	
Licensor

	
The University of Texas at El Paso (UTEP)  whose address is 500 W. University Avenue, El Paso, Texas 79968 on behalf of The Board of Regents of The University of Texas System, an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701.

	
 

	
Licensee

	
Premier Biomedical, Inc. a corporation with a mailing address of P.O. 25, Jackson Center PA 16133.

	
 

	
Contract Year and Contract Quarters

	
Contract Year is 12-month period ending on December 31 and Contract Quarters are 3-month periods ending on March 31, June 30, Sept. 30, Dec. 31

	
 

	
Territory

	
Worldwide

	
 

	
Field

	
x All fields

 

	
 

	
Patent Rights

	
 

 

	
 

	
App. No./

Date of Filing

	
Title

	
Inventor(s)

	
Jointly Owned? 

(Y/N; if Y, with whom?)

	
Prosecution Counsel

	
 

	
(F) 61/973908

(F) 4/2/14

Provisional patent application

	
CTLA-4 Blockade with Metronomic Chemotherapy

for the Treatment of Breast Cancer

	
Premier Biomedical Inc: Mitchel Felder;

UTEP: Robert Kirken, Giulio Francia

	
Premier Biomedical, Inc.

	
 Dr. Charles Landrum

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
USPTO Entity Status as of Effective Date

	
Check one box:

x Small

 ̈ Large

	
 

	
 

	
 

 

	
2.4.  Diligence Milestones

 

	 	
Milestones and deadlines

	
Milestone Events

	
Deadlines

	
 

	
Not Applicable

	
1.  Milestone None

	
None

 

	 
	
2

	

 

	
3.  Compensation

 

	
3.1(a)

	
Patent expenses due upon Effective Date

	
Amount

	
based on invoices received as of:

	 	 	
$0.0 – UTEP has not incurred past patent filing expenses

as of the Effective Date of this Agreement.

	
Past patent filing expenses for Application Number 61/973,908 Receipt date April 2, 2014 were paid directly by Licensee.

 

	
3.1(b)

	
Milestone  fees 

	
Milestone Events

	
Milestone Fees

	
 

	
Not Applicable

	
1. None

	
$ None

	
3.1(c)

	
Scheduled license fee payments

	
$1,000 due on Effective Date

	
3.1(d)

	
Sublicense Fees

	
10% of Non-Royalty Sublicensing Consideration for each sublicense

	
3.1(e)

	
Assignment fee

	
$50,000 One-time fee

	
3.2

	
Running royalty rate (applies to Sales by Licensee, Affiliates and Sublicensees)

	
10%  

	
3.3

	
Minimum royalty and Sublicense Fees

	
None

	
3.5

	
Equity Consideration

	
Is Licensor being issued stock or other equity of Licensee in partial consideration for entering into the Agreement?   ̈ Yes xNo. 

If yes, complete (a) and (b) below.

 

	 	
(a) Capitalization table at Effective Date 

on a fully-diluted basis

	
Shareholder

	
No. of Shares

	
% on fully-diluted basis

	 		
N/A

	
N/A

	
N/A

	 				
	 	
(b) Anti-dilution

	
N/A

	
 

	
 

 

	 
	
3

	

 

	
18. Contact Information

 

	 	
Licensee Contacts

	
Licensor Contacts

	
 

	
Contact for Notice:

Premier Biomedical, Inc.

P.O. 25

Jackson Center

PA 16133

Attn:  William Hartman

Phone: (724) 372-5242

 Email: williamahartman@aol.com

 

Payment and reporting contact:

Premier Biomedical, Inc.

1338 Springfield Church Rd.

Jackson Center, PA 16133

Attn: Heidi H. Carl

Phone: (724) 372-5651

Fax: (814) 786-7285

Email: heidicarl11@aol.com 

 

Patent prosecution contact:

Dr. William Brown

3610 Cherry Hill Drive

Orlando, FL 32822.

Fax: (407) 658-4064

Phone: (404) 395-9235

	
Contact for Notice:

Office of Technology Transfer

The University of Texas at El Paso

500 W. University Ave.

Administration Bldg., Room 209

El Paso, Texas 79968

Phone: (915) 747-8030

E-mail: techtransfer@utep.edu

 

Payment and reporting contact:

Checks payable to “The University of Texas at El Paso”

Office of Technology Transfer

The University of Texas at El Paso

500 W. University Ave.

Administration Bldg., Room 209

El Paso, Texas 79968

Phone: (915) 747-8030

E-mail: techtransfer@utep.edu

 

Patent prosecution contact:

Dr. Charles Landrum

5508 West Hwy. 290, Ste. 205

Austin, Texas 78735

Fax: (512) 233-1718

Phone: (512) 582-9150

E-mail: clandrum@landrumip.com

 

	
For Licensor Administrative Purposes Only

	
Changes to Standard Form Terms and Conditions

	
There have not been any revisions to Licensor’s standard form Terms and Conditions.

 

20. Special Provision. The Parties hereby agree to the following special provisions set forth in this Section 20 with respect to this Patent License Agreement.

 

None

 

21. No Other Promises and Agreements; Representation by Counsel. Licensee expressly warrants and represents and does hereby state and represent that no promise or agreement which is not herein expressed has been made to Licensee in executing this Patent License Agreement except those explicitly set forth herein and in the Terms and Conditions, and that Licensee is not relying upon any statement or representation of Licensor or its representatives. Licensee is relying on Licensee’s own judgment and has had the opportunity to be represented by legal counsel. Licensee hereby warrants and represents that Licensee understands and agrees to all terms and conditions set forth in this Patent License Agreement and said Terms and Conditions.

 

22. Deadline for Execution by Licensee. If this Patent License Agreement is executed first by the Licensor and is not executed by the Licensee and received by the Licensor at the address and in the manner set forth in Section 18 of the Terms and Conditions within 30 days of the date of signature set forth under the Licensor’s signature below, then this Patent License Agreement shall be null and void and of no further effect.

 

	 
	
4

	

 

IN WITNESS WHEREOF, the Parties hereto have caused their duly authorized representatives to execute this Patent License Agreement.

 

 

	LICENSOR:	 	LICENSEE:	 
	THE UNIVERSITY OF TEXAS AT EL PASO 		PREMIER BIOMEDICAL, INC.	
	ON BEHALF OF THE BOARD OF REGENTS			
	OF THE UNIVERSITY OF TEXAS SYSTEM			
	       	      				
	By:	/s/ Roberto Ossguada	 	By:	/s/ William A. Hartman	 
	Name:	Roberto Ossguada	 	Name:	William A. Hartman	 
	Title:	Vice President for Research	 	Title:	President and CEO	 
	 	The University of Texas at El Paso 				
	 	 			 	
	Date 3/5/15		Date 3/4/15	

 

	 
	
5

	

 

EXHIBIT A

TERMS AND CONDITIONS OF PATENT LICENSE

 

These Terms and Conditions of Patent License (“Terms and Conditions”) are incorporated by reference into the Patent License Agreement to which they are attached. All Section references in these Terms and Conditions shall be references to provisions in these Terms and Conditions unless explicitly stated otherwise.

 

	
1.

	
Definitions

 

“Actively Commercialize” means being engaged in an ongoing and active program directed towards commercial Sale of Licensed Products or Licensed Services and using best efforts to be reasonably funded in light of the research, development, manufacturing, regulatory, marketing or sales efforts required to make Licensed Products or Licensed Services available to the commercial market.

 

“Affiliate” means any business entity more than 50% owned by Licensee, any business entity which owns more than 50% of Licensee, or any business entity that is more than 50% owned by a business entity that owns more than 50% of Licensee.

 

“Agreement” means collectively (i) these Terms and Conditions, and (ii) the Patent License Agreement.

 

“Contract Quarter” means the three-month periods indicated as the Contract Quarter in Section 1 of the Patent License Agreement, or any stub period thereof at the commencement of the Agreement or the expiration or termination of the Agreement.

 

“Contract Year” means the 12-month periods indicated as the Contract Year in Section 1 of the Patent License Agreement, or any stub period thereof at the commencement of the Agreement or the expiration or termination of the Agreement.

 

“Effective Date” means the date indicated as the Effective Date in Section 1 of the Patent License Agreement.

 

“Fair Market Value” means the cash consideration an unaffiliated, unrelated buyer would pay in an arm’s length sale of a substantially identical item sold in the same quantity, under the same terms, and at the same time and place.

 

“Field” means the field indicated as the Field identified in Section 1 of the Patent License Agreement.

 

“Government” means any agency, department or other unit of the United States of America or the State of Texas.

 

“Gross Consideration” means all cash and non-cash consideration (e.g., securities).

 

“Licensed Process” means a method or process whose practice or use is covered by a Valid Claim.

 

	 
	
6

	

 

“Licensed Product” means any product or component (i) whose manufacture, use, sale, offer for sale or import is covered by any Valid Claim, or (ii) which is made using a Licensed Process or another Licensed Product.

 

“Licensed Service” means performance of a service for any consideration using a Licensed Product, or the practice of a Licensed Process. For clarity, research and development of Licensed Products by Licensee, its Affiliates, or a Sublicensee does not constitute a Licensed Service.

 

“Licensee” means the Party identified as the Licensee in Section 1 of the Patent License Agreement.

 

“Licensor” means the Party identified as the Licensor in Section 1 of the Patent License Agreement.

 

“Milestone Fees” means all fees identified as Milestone Fees in Section 3.1(b) of the Patent License Agreement.

 

“Net Product Sales” means the Gross Consideration from the Sale of Licensed Products less the following items directly attributable to the Sale of such Licensed Products that are specifically identified on the invoice for such Sale and borne by the Licensee, Affiliates, or Sublicensees as the seller: (a) discounts and rebates actually granted; (b) sales, value added, use and other taxes and government charges actually paid, excluding income taxes; (c) import and export duties actually paid; (d) freight, transport, packing and transit insurance charges actually paid or allowed; and (e) other amounts actually refunded, allowed or credited due to rejections or returns, but not exceeding the original invoiced amount.

 

Additionally, if Licensee, its Affiliates or Sublicensees use a Licensed Product or a Licensed Process for its own internal purposes or otherwise in a situation that does not involve a Sale for which a royalty is paid under Section 3.2, then Net Product Sales shall also include an amount equal to the customary sale price charged to a third party for the same Licensed Product or Licensed Process, except for a reasonable quantity used internally solely for testing or quality control purposes, marketing or demonstration purposes, or seeking governmental approval (e.g., U.S. Food and Drug Administration clinical trial). If there is no customary sale price, then the Net Product Sales shall be an amount equal to the Fair Market Value.

 

“Net Service Sales” means the Gross Consideration received from the Sale of Licensed Services less the following items, directly attributable to the Sale of such Licensed Services that are specifically identified on the invoice for such Sale and borne by the Licensee, Affiliates, or Sublicensees as the seller: (a) discounts and rebates actually granted; (b) sales, value added, use and other taxes and government charges actually paid, excluding income taxes; and (c) other amounts actually refunded, allowed or credited due to rejections or re-works, but not exceeding the original invoiced amount.

 

“Non-Royalty Sublicensing Consideration" means the Gross Consideration received by the Licensee or its Affiliate from a Sublicensee in consideration of the grant of a sublicense under the Patent Rights (including, without limitation, license or option or distribution fees, fees to maintain license rights, and bonus/milestone payments), but excluding amounts received as running royalties, a profit share, or other revenue sharing based on Net Product Sales or Net Service Sales for which Licensor receives a running royalty under Section 3.2. For the avoidance of doubt, Non-Royalty Sublicensing Consideration shall not include bona fide: (a) running royalties received by Licensee or an Affiliate based on Net Product Sales or Net Service Sales that are royalty-bearing to Licensor under Section 3.2, (b) purchase price for Licensee’s stock or other securities not in excess of Fair Market Value, and (iii) amounts paid and used exclusively for research and development of Licensed Products or Licensed Services by Licensee.

 

	 
	
7

	

 

“Patent License Agreement” means the particular Patent License Agreement to which these Terms and Conditions are attached and incorporated into by reference.

 

“Patent Rights” means the Licensor’s rights in: (a) the patents and patent applications listed in Section 1 of the Patent License Agreement; (b) all non-provisional patent applications that claim priority to any of the provisional applications listed in Section 1 of the Patent License Agreement; (c) all divisionals, continuations and such claims of continuations-in-part as are entitled to claim priority to the aforesaid patents and/or patent applications and all reissues, reexaminations, extensions, and foreign counterparts; and (d) any patents that issue with respect to any of the aforesaid patent applications; and (e) such other patents and patent applications as may arise during the term as defined in the Field. From time to time during the term of the Agreement, upon written agreement by both Parties, Licensee and Licensor shall update the list of all patent applications and patents within the Patent Rights, provided however that the absence of a patent or applications from such list shall in no way negate or diminish Licensee’s rights and license under such patents or applications not listed.

 

“Prosecution Counsel” means the law firm or attorney who is handling the prosecution of the Patent Rights. Prosecution Counsel as of the Effective Date is identified in Section 1 of the Patent License Agreement.

 

“Quarterly Payment Deadline” means the day that is 30 days after the last day of any particular Contract Quarter.

 

“Sell, Sale or Sold” means any transfer or other disposition of Licensed Products or Licensed Services for which consideration is received by Licensee, its Affiliates or Sublicensees. A Sale of Licensed Products or Licensed Services will be deemed completed at the time Licensee or its Affiliate or its Sublicensee receives payment.

 

“Sublicense Agreement” means any agreement or arrangement pursuant to which Licensee (or an Affiliate or Sublicensee) grants to any third party any of the license rights granted to the Licensee under the Agreement.

 

“Sublicense Fee” means the fee specified in Section 3.1(d) of the Patent License Agreement.

 

“Sublicensee” means any entity to whom an express sublicense has been granted under the Patent Rights. For clarity, a third party wholesaler or distributor who has no significant responsibility for marketing and promotion of the Licensed Product or Licensed Services within its distribution territory or field (i.e., the third party simply functions as a reseller), and who does not pay any consideration to Licensee or an Affiliate for such wholesale or distributor rights, shall not be deemed a Sublicensee; and the resale by such a wholesaler or distributor shall not be treated as royalty bearing Net Sales by a Sublicensee provided that a royalty is being paid by Licensee for the initial transfer to the wholesaler or distributor pursuant to Section 3.2. This definition does not limit Licensee’s rights to grant or authorize sublicenses under the Agreement.

 

“Territory” means the territory so indicated as the Territory in Section 1 of the Patent License Agreement subject to Section 10 (Export Compliance).

 

	 
	
8

	

 

“Valid Claim” means a claim of (i) an issued and unexpired patent included within the Patent Rights unless the claim has been held unenforceable or invalid by the final, un-reversed, and un-appealable decision of a court or other government body of competent jurisdiction, has been irretrievably abandoned or disclaimed, or has otherwise been finally admitted or determined to be invalid, un-patentable or unenforceable, whether through reissue, reexamination, disclaimer or otherwise, or (ii) a pending patent application within the Patent Rights to the extent the claim continues to be prosecuted in good faith.

 

	
2.

	
License Grant and Commercialization

 

	 	
2.1

	
Grant

 

	 	 	
(a)

	
Licensor grants to Licensee a royalty-bearing exclusive license under Patent Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field in the Territory and to perform Licensed Services in the Field in the Territory.

	 	 	
 

	 
	 	 	
(b)

	
This grant is subject to (i) the payment by Licensee to Licensor of all consideration required under the Agreement, (ii) any rights of, or obligations to, the Government as set forth in Section 11.2 (Government Rights), and (iii) rights retained by Licensor to:

 

	 	 	 	
(1)

	
Publish the scientific findings from research related to the Patent Rights; and

	 	 	 	
 

	 
	 	 	 	
(2)

	
Manufacture, have manufactured and use the Patent Rights for teaching, research, patient care, education, and other educationally-related purposes; and

	 	 	 	
 

	 
	 	 	 	
(3)

	
Grant rights to, and transfer material embodiments of, the Patent Rights to other academic institutions or non-profit research institutions for the purposes identified in clauses (1) and (2) above.

	 	 	 	
 

	 
	 	 	 	
(c)

	
Licensor reserves all rights not expressly granted in the Agreement and disclaims the grant of any implied rights to Licensee.

 

	 	
2.2

	
Affiliates

	 	
 

	
Licensee may extend the license granted herein to any Affiliate provided that the Affiliate agrees in writing to be bound by the Agreement to the same extent as Licensee. For the sake of clarity, any specific reference to “Licensee” herein shall include such Affiliate regardless of whether a specific reference to an “Affiliate” is made in such provision. Licensee agrees to deliver such written agreement to Licensor within 30 calendar days following execution.

 

	 	
2.3

	
Sublicensing

	 	
 

	
Licensee has the right to grant Sublicense Agreements under the Patent Rights consistent with the terms of the Agreement, subject to the following:

 

	 	 	
(a)

	
A Sublicense Agreement shall not exceed the scope and rights granted to Licensee hereunder. Sublicensee must agree in writing to be bound by the applicable terms and conditions of the Agreement and shall indicate that Licensor is a third party beneficiary and entitled to enforce the terms and conditions of the Sublicense Agreement applicable to the Agreement. In the event of termination of this Agreement, continued sublicense rights shall be governed by Section 7.5(a) (Effect of Termination). Licensee may grant a Sublicensee the right to grant further sub-Sublicense Agreements, in which case such sub-Sublicense Agreements shall be treated as “Sublicense Agreements” and such sub-Sublicensees shall be treated as “Sublicensees” for purposes of the Agreement.

 

	 
	
9

	

 

	 	 	
(b)

	
Licensee shall deliver to Licensor a true, complete, and correct copy of each Sublicense Agreement granted by Licensee, Affiliate or Sublicensee, and any modification or termination thereof, within 30 days following the applicable execution, modification, or termination of such Sublicense Agreement. If the Sublicense Agreement is not in English, Licensee shall provide Licensor an accurate English translation in addition to a copy of the original agreement.

	 	 	
 

	 
	 	 	
(c)

	
Notwithstanding any such Sublicense Agreement, Licensee will remain primarily liable to Licensor for all of the Licensee’s duties and obligations contained in the Agreement, including without limitation the payment of running royalties due under Section 3.2 whether or not paid to Licensee by a Sublicensee. Any act or omission of a Sublicensee that would be a breach of the Agreement if performed by Licensee will be deemed to be a breach by Licensee unless Licensee complies with the remaining provisions of this paragraph. Each Sublicense Agreement will contain a right of termination by Licensee in the event that the Sublicensee breaches the payment or reporting obligations affecting Licensor or any other terms and conditions of the Sublicense Agreement that would constitute a breach of the Agreement if such acts were performed by Licensee. In the event of a Sublicensee breach, and if after a reasonable opportunity to cure as provided in any such Sublicense Agreement (not to exceed 30 days for a payment breach and 60 days for a non-payment breach), such Sublicensee fails to cure such Sublicensee breach, then the Licensee will terminate the Sublicense Agreement within 30 days thereafter, with copy of such written notice of termination to Licensor, unless agreed to in writing otherwise by Licensor.

 

	 	
2.4

	
Diligent Commercialization

	 	
 

	
Licensee by itself or through its Affiliates and Sublicensees will use its best efforts to Actively Commercialize and make Licensed Products and/or Licensed Services (as applicable) commercially available in the Field within the Territory. Without limiting the foregoing, Licensee will:

 

	 	 	
(a)

	
use its best efforts to maintain a bona fide, funded, ongoing and active research, development, manufacturing, regulatory, marketing or sales program to make License Products and/or Licensed Services commercially available to the public as soon as commercially practicable, and

	 	 	
 

	 
	 	 	
(b)

	
fulfill the milestone events specified in Section 2.4 of the Patent License Agreement by the deadlines indicated therein.

 

It shall be considered a breach of the Agreement if Licensee fails to Actively Commercialize Licensed Products or Licensed Services.

 

	 
	
10

	

 

	
3.

	
Compensation

 

In consideration of rights granted to Licensee, Licensee will pay Licensor the following fees and royalties. All fees and royalties are not refundable and are not creditable against other fees and royalties. Each payment will reference the Patent License Agreement number and will be sent to Licensor’s payment and accounting contact in Section 18 (Notices) of the Patent License Agreement.

 

	 	
3.1

	
Non-Royalty Payments due from Licensee

 

	 	 	
(a)

	
Patent Expenses. Licensee will reimburse Licensor for the past patent expenses stated in Section 3.1(a) of the Patent License Agreement within 15 days after the Effective Date. The stated amount is the current estimate for past patent expenses based on invoices received by the Licensor through the stated date. Licensee’s obligations to pay all past and future patent expenses pursuant to Section 6 (Legal Expenses and Prosecution) will not be limited by such amount.

	 	 	
 

	 
	 	 	
(b)

	
Milestone Fees. Licensee will pay Milestone Fees indicated in Section 3.1(b) of the Patent License Agreement by the Quarterly Payment Deadline of the first to occur of (i) the achievement of the applicable milestone, or (ii) the deadline for such milestone set forth in Section 3.1(b) of the Patent License Agreement, as applicable.

	 	 	
 

	 
	 	 	
(c)

	
Scheduled License Fees. Licensee will pay license fees in the amounts set forth in Sections 3.1(c) of the Patent License Agreement in accordance with the stated schedule.

	 	 	
 

	 
	 	 	
(d)

	
Sublicense Fees. Licensee will pay Sublicense Fees indicated in Section 3.1(d) of the Patent License Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

	 	 	
 

	 
	 	 	
(e)

	
Assignment Fee. Licensee will pay the assignment fee set forth in Section 3.1(e) of the Patent License Agreement within 15 days of the assignment of the Agreement.

	 	 	
 

	 
	 	 	
(f)

	
Corporate Expenses. Licensee will reimburse Licensor within 30 days after receipt of invoice from Licensor for all documented, out-of-pocket expenses incurred by Licensor for review, preparation, and negotiation of this Agreement, including future amendments, assignments, and other corporate-related instruments.

 

	 	
3.2

	
Royalties

	 	
 

	
Licensee will pay a running royalty at the rate set forth in Section 3.2 of the Patent License Agreement on Net Product Sales and Net Service Sales in each Contract Quarter, payable on or before the Quarterly Payment Deadline for such Contract Quarter, subject to the following:

 

	 	 	
(a)

	
No more than one royalty shall be paid to Licensor hereunder with respect to the Sale of any one unit of Licensed Product or Licensed Service, whether or not more than one patent or Valid Claim is applicable to the Licensed Product or Licensed Service, or the development, manufacture, or performance thereof.

 

	 
	
11

	

 

	 	 	
(b)

	
No royalty shall be payable under this Section 3.2 with respect to (i) Sales to an Affiliate or Sublicensee of a particular unit of Licensed Product that is used by such Affiliate or Sublicensee to perform a Licensed Service if Licensor is paid a royalty on the Sale of such Licensed Service, (ii) the Sale of Licensed Products between or among Licensee, its Affiliates, and Sublicensees for re-sale purposes, provided Licensor is paid a royalty with respect to the re-sale, or (iii) payments that constitute Non-Royalty Sublicensing Consideration.

 

	 	
3.4

	
Minimum Royalties and Sublicense Fees

	 	
 

	
If royalties and Sublicense Fees paid to Licensor do not reach the minimum royalty amounts stated in Section 3.3 of the Patent License Agreement for the specified periods, Licensee will pay Licensor on or before the Quarterly Payment Deadline for the last Contract Quarter in the stated period an additional amount equal to the difference between the stated minimum royalty amount and the actual royalties and Sublicense Fees paid to Licensor.

 

	 	
3.3

	
Non-cash Consideration

	 	
 

	
If Licensee receives or anticipates receipt of non-cash consideration from Sales or Sublicenses, the manner in which Licensor will receive its compensation under the Agreement with respect to such non-cash consideration will be negotiated in good faith and timely agreed to by the Parties.

 

	
4.

	
Reports and Plans

	
 

	 
	
 

	
The reports specified in this Section 4 will be sent to Licensor’s payment and reporting contact identified in Section 18 (Notices) of the Patent License Agreement. If Licensor requests to have information submitted in a particular format, Licensee will use reasonable efforts to comply with such request.

 

	 	
4.1

	
Quarterly Payment and Milestone Reports

	 	
 

	
On or before each Quarterly Payment Deadline, Licensee will deliver to Licensor a true and accurate report, certified by an officer of Licensee, giving such particulars of the business conducted by Licensee, its Affiliates and its Sublicensees (including copies of reports provided by Sublicensees and Affiliates to Licensee) during the preceding Contract Quarter under the Agreement as necessary for Licensor to account for Licensee’s payments, including royalties, hereunder, even if no payments are due. The reports shall continue to be delivered after the termination or expiration of the Agreement until such time as all Licensed Products permitted to be Sold after termination or expiration have been Sold or destroyed. Licensee shall provide information in sufficient detail to enable the royalties payable hereunder to be determined and to calculate all of the amounts payable under the Agreement. The report shall include:

 

	 	 	
(a)

	
The name of the Licensee, the Patent License Agreement number, and the period covered by the report;

	 	 	
 

	 
	 	 	
(b)

	
The name of any Affiliates and Sublicensees whose activities are also covered by the report;

 

	 
	
12

	

 

	 	 	
(c)

	
Identification of each Licensed Product and Licensed Service for which any royalty payments have become payable;

	 	 	
 

	 
	 	 	
(d)

	
Net Product Sales and Net Service Sales segregated on a product-by-product basis, and a country-by-country basis, or an affirmative statement that no Sales were made. The report shall also itemize the permitted deductions from the Gross Consideration used to arrive at the resulting Net Product Sales and Net Service Sales, on a product-by-product and country-by-country basis;

	 	 	
 

	 
	 	 	
(e)

	
The applicable royalty rate;

	 	 	
 

	 
	 	 	
(f)

	
An affirmative statement of whether any milestones with deadlines in that Contract Quarter under Section 2.4 and any milestones under Section 3.1(b) were met or not, and the resulting Milestone Fee payable;

	 	 	
 

	 
	 	 	
(g)

	
Non-Royalty Sublicensing Consideration received by Licensee segregated on a Sublicense-by-Sublicense basis, or an affirmative statement that none was received;

	 	 	
 

	 
	 	 	
(h)

	
If any consideration was received in currencies other than U.S. dollars, the report shall describe the currency exchange calculations; and

	 	 	
 

	 
	 	 	
(i)

	
Any changes in accounting methodologies used to account for and calculate the items included in the report since the previous report.

 

	 	
4.2

	
Annual Written Progress Report and Commercialization Plan

	 	
 

	
Within 45 days following the end of each Contract Year, Licensee will deliver to Licensor a true and accurate signed written progress report and commercialization plan, certified by an officer of Licensee, that summarizes (i) Licensee’s efforts and accomplishments during the Contract Year to Actively Commercialize Licensed Products and Licensed Services, and (ii) Licensee’s development and commercialization plans with respect to Licensed Products and Licensed Services for the next Contract Year. The report shall also cover such activities by Affiliates and Sublicensees. The report shall contain the following information to the extent relevant to the activities under the Agreement:

 

	 	 	
(a)

	
The name of the Licensee, the Patent License Agreement number, the names of any Affiliates and Sublicensees, and the products and services being developed and/or commercialized;

	 	 	
 

	 
	 	 	
(b)

	
The progress toward completing and the plans for completing the applicable milestone events pursuant to Sections 2.4 and 3.1(b);

	 	 	
 

	 
	 	 	
(b)

	
The research and development activities, including status and plans for obtaining any necessary governmental approvals, performed during the past year, and the plans for research and development activities for the next year; and

	 	 	
 

	 
	 	 	
(d)

	
The marketing activities for the past year and planned for the next year, and Licensee’s internal estimate for Sales for the next year.

 

	 
	
13

	

 

	 	
4.3

	
Government and Economic Development Reporting

	 	
 

	
If Licensor requests, Licensee will provide information for Licensor’s Government and economic development reporting purposes, including the following:

 

	 	 	
(a)

	
Number and geographic location of new full-time employees created during the past Contract Year; total number and geographic location of full-time employees of Licensee at the end of such Contract Year;

	 	 	
 

	 
	 	 	
(b)

	
Dollar amount of new equity financing received by Licensee during the past Contract Year, and current capitalization, including number and class of outstanding securities;

	 	 	
 

	 
	 	 	
(c)

	
Location and square footage of facilities; and

	 	 	
 

	 
	 	 	
(d)

	
Other information required under Federal and state law.

 

This information shall be treated as Licensee’s Confidential Information; provided that Licensor is entitled to combine such information with similar information from other Licensor licensees and publicly report such combined aggregate information, without identifying Licensee’s separate specific applicable numbers. If and when Licensee has more than 200 full-time employees, then no further economic development reports will be required from Licensee.

 

	
5.

	
Payment, Records, and Audits

 

	 	
5.1

	
Payments

	 	
 

	
All amounts referred to in the Patent License Agreement are expressed in U.S. dollars without deductions for taxes, assessments, fees, or charges of any kind. Each payment will reference the agreement number set forth at the beginning of the Patent License Agreement. All payments to Licensor will be made in U.S. dollars by check or wire transfer (Licensee to pay all wire transfer fees) payable to the payee identified in Section 18 of the Patent License Agreement and sent to the payment and reporting contact in Section 18 (Notices) of the Patent License Agreement.

	 	
 

	 
	 	
5.2

	
Sales Outside the U.S.

	 	
 

	
If any currency conversion shall be required in connection with the calculation of payments hereunder, such conversion shall be made using the rate used by Licensee for its financial reporting purposes in accordance with Generally Accepted Accounting Principles (or foreign equivalent) or, in the absence of such rate, using the average of the buying and selling exchange rate for conversion between the foreign currency and U.S. Dollars, for current transactions as reported in The Wall Street Journal on the last business days of the Contract Quarter to which such payment pertains. Licensee may not make any tax withholdings from payments to Licensor, but Licensor agrees to supply to Licensee, upon written request, appropriate evidence from appropriate U.S. governmental agencies showing that Licensor is a resident of the United States of America for purposes of the U.S. income tax laws and is tax-exempt under such income tax laws.

	 	
 

	 
	 	
5.3

	
Late Payments

	 	
 

	
Amounts that are not paid when due will accrue a late charge from the due date until paid, at a rate equal to 1.0% per month (or the maximum allowed by law, if less).

 

	 
	
14

	

 

	 	
5.4

	
Records

	 	
 

	
For a period of six years after the Contract Quarter to which the records pertain, Licensee agrees that it and its Affiliates and Sublicensees will each keep complete and accurate records of their Sales, Net Product Sales, Net Service Sales, Milestone Fees, and Non-Royalty Sublicensing Consideration in sufficient detail to enable such payments to be determined and audited.

	 	
 

	 
	 	
5.5

	
Auditing

	 	
 

	
Licensee and its Affiliates will permit Licensor or its representatives, at Licensor’s expense, to periodically examine books, ledgers, and records during regular business hours, at Licensee’s or its Affiliate’s place of business, on at least 30 days advance notice, to the extent necessary to verify any payment or report required under the Agreement. For each Sublicensee, Licensee shall obtain such audit rights for Licensor or itself. If Licensee obtains such audit rights for itself, it will promptly conduct an audit of the Sublicensee’s records upon Licensor’s request, and Licensee will furnish to Licensor a copy of the findings from such audit. No more than one audit of Licensee, each Affiliate, and each Sublicensee shall be conducted under this Section 5.5 in any calendar year. If any amounts due Licensor have been underpaid, then Licensee shall immediately pay Licensor the amount of such underpayment plus accrued interest due in accordance with Section 5.3. If the amount of underpayment is equal to or greater than 5% of the total amount due for the records so examined, Licensee will pay the cost of such audit. Such audits may, at Licensor’s sole discretion, consist of a self-audit conducted by Licensee at Licensee’s expense and certified in writing by an authorized officer of Licensee. All information examined pursuant to this Section 5.5 shall be deemed to be the Confidential Information of the Licensee. Further, whenever Licensee and/or its Affiliates and Sublicensees has its books and records audited by an independent certified public accountant, Licensee and/or its Affiliates and Sublicensees will, within 30 days of the conclusion of such audit, provide Licensor with a written statement of said auditor, setting forth the calculation of amounts due to Licensor over the time period audited, as determined from the books and records of the Licensee, Affiliate or Sublicensee; but said auditor does not need to give any audit opinion with said statement.

 

	
6.

	
Legal Expenses and Prosecution

 

	 	
6.1

	
Legal Expenses

	 	
 

	
Licensee shall pay for all past documented, out-of-pocket expenses incurred by Licensor for filing, prosecuting, defending and maintaining Patent Rights and related patent searches through the Effective Date of the Agreement, including those identified in Section 3.1(a) of the Patent License Agreement, and all such future expenses incurred by Licensor, for so long as, and in such countries as the Agreement remains in effect. Licensee will pay all legal expenses (except for the payment called for under Section 3.1(a)), including past expenses that have not been invoiced as of the date indicated in Section 3.1(a) of the Patent License Agreement and future expenses, including with respect to an assignment of this Agreement, within 30 days after Licensee’s receipt of an invoice. At the election of Licensor, Licensee will either pay Prosecution Counsel directly for patent expenses or will reimburse Licensor for such patent expenses. Patent expense payment delinquencies (whether owed directly to Prosecution Counsel or to Licensor) will be considered a payment default under Section 7.3(a).

 

	 
	
15

	

 

	 	
6.2

	
Direction of Prosecution

	 	
 

	
Licensor will confer with Licensee to develop a strategy for the prosecution and maintenance of Patent Rights. Licensor will request that copies of all documents prepared by the Prosecution Counsel for submission to governmental patent offices be provided to Licensee for review and comment prior to filing, to the extent practicable under the circumstances. At its discretion, Licensor may allow Licensee to instruct Prosecution Counsel directly, provided, that (a) Licensor will maintain final authority in all decisions regarding the prosecution and maintenance of the Patent Rights, (b) Licensor may revoke this authorization to instruct Prosecution Counsel directly at any time, and (c) the Prosecution Counsel remains counsel to the Licensor with an appropriate contract (and shall not jointly represent Licensee unless requested by Licensee and approved by Licensor, and an appropriate engagement letter and conflict waiver are in effect). If Licensee wishes to instruct Prosecution Counsel directly or to request a change in Prosecution Counsel, Licensee may do so by following the Licensor’s procedures for such. Licensor reserves in its sole discretion the ability to change Prosecution Counsel and to approve or disapprove any requested changes by Licensee. The Parties agree that they share a common legal interest to get valid enforceable patents and that Licensee will maintain as privileged all information received pursuant to this Section.

	 	
 

	 
	 	
6.3

	
Ownership

	 	
 

	
All patent applications and patents will be in the name of Licensor (and any co-owner identified in Section 1 of the Patent License Agreement) and owned by Licensor (and such co-owner, if any). No payments due under the Agreement will be reduced as the result of co-ownership interests in the Patent Rights by Licensee or any other party.

	 	
 

	 
	 	
6.4

	
Foreign Filings

	 	
 

	
In addition to the U.S., the Patent Rights shall, subject to applicable bar dates, be pursued in such foreign countries as Licensee so designates in writing to Licensor in sufficient time to reasonably enable the preparation of such additional filings, and in those foreign countries in which Licensor has filed applications prior to the Effective Date. If Licensee does not choose to pursue patent rights in a particular foreign country and Licensor chooses to do so, Licensee shall so notify Licensor and thereafter said patent application or patent shall no longer be included in the Patent Rights and Licensee shall have no further rights thereto. Licensor shall have the right to make alternative arrangements with Licensee for upfront payment of foreign patent expenses.

	 	
 

	 
	 	
6.5

	
Withdrawal from Paying Patent Costs

	 	
 

	
If at any time Licensee wishes to cease paying for any costs for a particular Patent Right or for patent prosecution in a particular jurisdiction, Licensee must give Licensor at least 90 days prior written notice and Licensee will continue to be obligated to pay for the patent costs which reasonably accrue during said notice period. Thereafter, said patent application or patent shall no longer be included in the Patent Rights and Licensee shall have no further rights thereto.

	 	
 

	 
	 	
6.6

	
U.S. Patent and Trademark Office Entity Size Status

	 	
 

	
Licensee represents that as of the Effective Date the entity size status of Licensee in accordance with the regulations of the U.S. Patent and Trademark Office is as set forth in Section 1 of the Patent License Agreement. Licensee will inform Licensor in writing on a timely basis of any change in its U.S. Patent and Trademark Office entity size status.

 

	 
	
16

	

 

 

	
7.

	
Term and Termination

 

	 	
7.1

	
Term

	 	
 

	
Unless earlier terminated as provided herein, the term of the Agreement will commence on the Effective Date and continue until the last date of expiration or termination of the Patent Rights.

	 	
 

	 
	 	
7.2

	
Termination by Licensee

	 	
 

	
Licensee, at its option, may terminate the Agreement by providing Licensor written notice of intent to terminate, which termination shall be effective 90 days following receipt of such notice by Licensor.

	 	
 

	 
	 	
7.3

	
Termination by Licensor

	 	
 

	
Licensor, at its option, may immediately terminate the Agreement, or any part of Patent Rights, or any part of Field, or any part of Territory, or the exclusive nature of the license grant, upon delivery of written notice to Licensee of Licensor’s decision to terminate, if any of the following occur:

 

	 	 	
(a)

	
Licensee becomes in arrears in any payments due under the Agreement, and Licensee fails to make the required payment within 30 days after delivery of written notice from Licensor; or

	 	 	
 

	 
	 	 	
(b)

	
Licensee is in breach of any non-payment provision of the Agreement, and does not cure such breach within 60 days after delivery of written notice from Licensor; or

	 	 	
 

	 
	 	 	
(c)

	
Licensor delivers notice to Licensee of three or more actual breaches of the Agreement in any 12-month period, even in the event that Licensee cures such breaches in the allowed period; or

	 	 	
 

	 
	 	 	
(d)

	
Licensee or its Affiliate or Sublicensee initiates any proceeding or action to challenge the validity, enforceability, or scope of one or more of the Patent Rights, or assist a third party in pursuing such a proceeding or action.

 

	 	
7.4

	
Other Conditions of Termination

	 	
 

	
The Agreement will terminate:

 

	 	 	
(a)

	
Immediately without the necessity of any action being taken by Licensor or Licensee, (i) if Licensee becomes bankrupt or insolvent, or (ii) Licensee’s Board of Directors elects to liquidate its assets or dissolve its business, or (iii) Licensee ceases its business operations, or (iv) Licensee makes an assignment for the benefit of creditors or (v) if the business or assets of Licensee are otherwise placed in the hands of a receiver, assignee or trustee, whether by voluntary act of Licensee or otherwise; or

	 	 	
 

	 
	 	 	
(b)

	
At any time by mutual written agreement between Licensee and Licensor.

 

	 	
7.5

	
Effect of Termination

	 	
 

	
If the Agreement is terminated for any reason:

 

	 	 	
(a)

	
All rights and licenses of Sublicensees shall terminate upon termination of the Agreement; provided however, if the Sublicense Agreement is for all of the Field for all of the Territory, and the Sublicensee is in good standing and agrees in writing to assume all of the obligations of Licensee and provides Licensor with written notice thereof within 30 days after termination of the Agreement, then such Sublicense Agreement shall survive; and

 

	 
	
17

	

 

	 	 	
(b)

	
Licensee shall cease making, having made, distributing, having distributed, using, selling, offering to sell, leasing, loaning and importing any Licensed Products and performing Licensed Services by the effective date of termination; and

	 	 	
 

	 
	 	 	
(c)

	
Licensee shall tender payment of all accrued royalties and other payments due to Licensor as of the effective date of termination; and

	 	 	
 

	 
	 	 	
(d)

	
Nothing in the Agreement will be construed to release either Party from any obligation that matured prior to the effective date of termination; and

	 	 	
 

	 
	 	 	
(e)

	
The provisions of Sections 8 (Confidentiality), 9 (Infringement and Litigation), 11 (Representations and Disclaimers), 12 (Limit of Liability), 13 (Indemnification), 14 (Insurance), 17 (Use of Name), 18 (Notices), and 19 (General Provisions) will survive any termination or expiration of the Agreement. In addition, the provisions of Sections 3 (Compensation), 4.1 (Quarterly Payment and Milestone Reports), 5 (Payment, Records and Audits), and 6.1 (Legal Expenses) shall survive with respect to all activities and payment obligations accruing prior to the termination or expiration of the Agreement.

 

	
8.

	
Confidentiality

 

	 	
8.1

	
Definition

	 	
 

	
“Confidential Information” means all information that is of a confidential and proprietary nature to Licensor or Licensee and provided by one Party to the other Party under the Agreement.

	 	
 

	 
	 	
8.2

	
Protection and Marking

	 	
 

	
Licensor and Licensee each agree that all Confidential Information disclosed in tangible form, and marked “confidential” and forwarded to one by the other, or if disclosed orally, is designated as confidential at the time of disclosure: (i) is to be held in strict confidence by the receiving Party, (ii) is to be used by and under authority of the receiving Party only as authorized in the Agreement, and (iii) shall not be disclosed by the receiving Party, its agents or employees without the prior written consent of the disclosing Party or as authorized in the Agreement. Licensee has the right to use and disclose Confidential Information of Licensor reasonably in connection with the exercise of its rights under the Agreement, including without limitation disclosing to Affiliates, Sublicensees, potential investors, acquirers, and others on a need to know basis, if such Confidential Information is provided under conditions which reasonably protect the confidentiality thereof. Each Party’s obligation of confidence hereunder includes, without limitation, using at least the same degree of care with the disclosing Party’s Confidential Information as it uses to protect its own Confidential Information, but always at least a reasonable degree of care.

	 	
 

	 
	 	
8.3

	
Confidentiality of Terms of Agreement

	 	
 

	
Each Party agrees not to disclose to any third party the terms of the Agreement without the prior written consent of the other Party hereto, except each Party may disclose the terms of the Agreement: (a) to advisors, actual or potential Sublicensees, acquirers or investors, and others on a need to know basis, in each case, under appropriate confidentiality obligations substantially similar to those of this Section 8; and (b) to the extent necessary to comply with applicable laws and court orders (including, without limitation, The Texas Public Information Act, as may be amended from time to time, other open records laws, decisions and rulings, and securities laws, regulations and guidance). If the Agreement is not for all fields of use, then Licensor may disclose the existence of the Agreement and the Field to other potential third party licensees. Notwithstanding the foregoing, the existence of the Agreement shall not be considered Confidential Information.

 

	 
	
18

	

 

	 	
8.4

	
Disclosure Required by Court Order or Law

	 	
 

	
If the receiving Party is required to disclose Confidential Information of another Party hereto, or any terms of the Agreement, pursuant to the order or requirement of a court, administrative agency, or other governmental body or applicable law, the receiving Party may disclose such Confidential Information or terms to the extent required, provided that the receiving Party shall use reasonable efforts to provide the disclosing Party with reasonable advance notice thereof to enable the disclosing Party to seek a protective order and otherwise seek to prevent such disclosure.

	 	
 

	 
	 	
8.5

	
Copies

	 	
 

	
Each Party agrees not to copy or record any of the Confidential Information of the other Party, except as reasonably necessary to exercise its rights or perform its obligations under the Agreement, and for archival and legal purposes.

	 	
 

	 
	 	
8.6

	
Continuing Obligations

	 	
 

	
Subject to the exclusions listed in Section 8.7, the Parties’ confidentiality obligations under the Agreement will survive termination of the Agreement and will continue for a period of five years thereafter.

	 	
 

	 
	 	
8.7

	
Exclusions

	 	
 

	
Information shall not be considered Confidential Information of a disclosing Party under the Agreement to the extent that the receiving Party can establish by competent written proof that such information:

 

	 	 	
(a)

	
Was in the public domain at the time of disclosure; or

	 	 	
 

	 
	 	 	
(b)

	
Later became part of the public domain through no act or omission of the recipient Party, its employees, agents, successors or assigns in breach of the Agreement; or

	 	 	
 

	 
	 	 	
(c)

	
Was lawfully disclosed to the recipient Party by a third party having the right to disclose it not under an obligation of confidentiality; or

	 	 	
 

	 
	 	 	
(d)

	
Was already known by the recipient Party at the time of disclosure; or

	 	 	
 

	 
	 	 	
(e)

	
Was independently developed by the recipient Party without use of the disclosing Party’s Confidential Information.

 

	 	
8.8

	
Copyright Notice

	 	
 

	
The placement of a copyright notice on any Confidential Information will not be construed to mean that such information has been published and will not release the other Party from its obligation of confidentiality hereunder

 

	 
	
19

	

 

	
9.

	
Infringement and Litigation

 

	 	
9.1

	
Notification

	 	
 

	
If either Licensor’s designated office for technology commercialization or Licensee becomes aware of any infringement or potential infringement of Patent Rights, each Party shall promptly notify the other of such in writing.

	 	
 

	 
	 	
9.2

	
Licensee’s Enforcement Rights

	 	
 

	
Licensee shall enforce the Patent Rights against any infringement by a third party. Licensee shall be responsible for payment of all fees and expenses associated with such enforcement incurred by Licensee and incurred by Licensor in providing cooperation or joining as a party as provided in Section 9.4. Licensee agrees to pay Licensor a percentage equivalent to the Sublicense Fee rate set forth in Section 3.1(d) of the Patent License Agreement on any monetary recovery, including any punitive damages, in excess of Licensee’s documented, third-party expenses in enforcing the Patent Rights and amounts actually reimbursed to Licensor under this Section 9.2.

	 	
 

	 
	 	
9.3

	
Licensor’s Enforcement Rights

	 	
 

	
If Licensee does not file suit within six months after a written request by Licensor to initiate an infringement action, then Licensor shall have the right, at its sole discretion, to bring suit to enforce any Patent Right licensed hereunder against the infringing activities, with Licensor retaining all recoveries from such enforcement. If Licensor pursues such infringement action, Licensor may, as part of the resolution of such efforts, grant non-exclusive license rights to the alleged infringer notwithstanding Licensee’s exclusive license rights.

	 	
 

	 
	 	
9.4

	
Cooperation between Licensor and Licensee

	 	
 

	
In any infringement suit or dispute, the Parties agree to cooperate fully with each other. At the request of the Party bringing suit, the other Party will permit reasonable access after reasonable advance notice to all relevant personnel, records, papers, information, samples, specimens, etc., during regular business hours.

	 	
 

	 
	 	
 

	
If it is necessary to name Licensor as a party in such action, then Licensee must first obtain Licensor’s prior written permission, which permission shall not be unreasonably withheld, provided that Licensor shall have reasonable prior input on choice of counsel on any matter where such counsel represents Licensor, and Licensee and such counsel agree to follow all required procedures of the Texas Attorney General regarding retention of outside counsel for state entities.

 

	
10.

	
Export Compliance

	
 

	 
	
 

	
Licensee understands that the Arms Export Control Act (AECA), including its implementing International Traffic In Arms Regulations (ITAR), and the Export Administration Act (EAA), including its Export Administration Regulations (EAR), are some (but not all) of the laws and regulations that comprise the U.S. export laws and regulations. Licensee further understands that the U.S. export laws and regulations include (but are not limited to): (a) ITAR and EAR product/service/data-specific requirements; (b) ITAR and EAR ultimate destination-specific requirements; (c) ITAR and EAR end user-specific requirements; (d) Foreign Corrupt Practices Act; and (e) anti-boycott laws and regulations. Licensee will comply with all then-current applicable export laws and regulations of the U.S. Government (and other applicable U.S. laws and regulations) pertaining to the Licensed Products and Licensed Services (including any associated products, items, articles, computer software, media, services, technical data, and other information). Licensee certifies that it will not, directly or indirectly, export (including any deemed export), nor re-export (including any deemed re-export) the Licensed Products and Licensed Services (including any associated products, items, articles, computer software, media, services, technical data, and other information) in violation of applicable U.S. laws and regulations. Licensee will include a provision in its agreements, substantially similar to this Section 10, with its Sublicensees, third party wholesalers and distributors, and physicians, hospitals or other healthcare providers who purchase a Licensed Product, requiring that these parties comply with all then-current applicable U.S. export laws and regulations and other applicable U.S. laws and regulations.

 

	 
	
20

	

 

	
11.

	
Representations and Disclaimers

 

	 	
11.1

	
Licensor Representations

	 	
 

	
Except for the rights, if any, of the Government as set forth in Section 11.2, Licensor represents and warrants to Licensee that to the knowledge of Licensor’s designated office for technology commercialization (i) Licensor is the owner or agent of the entire right, title, and interest in and to Patent Rights (other than the right, title and interest of any joint owner identified in Section 1 of the Patent License Agreement), (ii) Licensor has the right to grant licenses hereunder, and (iii) Licensor has not knowingly granted and will not knowingly grant licenses or other rights under the Patent Rights that are in conflict with the terms and conditions in the Agreement.

	 	
 

	 
	 	
11.2

	
Government Rights

	 	
 

	
Licensee understands that Patent Rights may have been developed under a funding agreement with Government and, if so, that Government may have certain rights relative thereto. The Agreement is made subject to the Government’s rights under any such agreement and under any applicable Government law or regulation. To the extent that there is a conflict between any such agreement, such applicable law or regulation and the Agreement, the terms of such Government agreement, and applicable law or regulation, shall prevail. Licensee agrees that, to the extent required by U.S. laws and regulations, Licensed Products used or Sold in the U.S. will be manufactured substantially in the U.S., unless a written waiver is obtained in advance from the U.S. Government.

	 	
 

	 
	 	
11.3

	
Licensor Disclaimers

	 	
 

	
EXCEPT AS SPECIFICALLY SET FORTH IN SECTION 11.1, LICENSEE UNDERSTANDS AND AGREES THAT LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, AS TO THE LICENSED PRODUCTS OR LICENSED SERVICES, OR AS TO THE OPERABILITY OR FITNESS FOR ANY USE OR PARTICULAR PURPOSE, MERCHANTABILITY, SAFETY, EFFICACY, APPROVABILITY BY REGULATORY AUTHORITIES, TIME AND COST OF DEVELOPMENT, PATENTABILITY, AND/OR BREADTH OF PATENT RIGHTS. LICENSOR MAKES NO REPRESENTATION AS TO WHETHER ANY PATENT WITHIN PATENT RIGHTS IS VALID, OR AS TO WHETHER THERE ARE ANY PATENTS NOW HELD, OR WHICH WILL BE HELD, BY OTHERS OR BY LICENSOR THAT MIGHT BE REQUIRED FOR USE OF PATENT RIGHTS IN FIELD. NOTHING IN THE AGREEMENT WILL BE CONSTRUED AS CONFERRING BY IMPLICATION, ESTOPPEL OR OTHERWISE ANY LICENSE OR RIGHTS TO ANY PATENTS OR TECHNOLOGY OF LICENSOR OTHER THAN THE PATENT RIGHTS, WHETHER SUCH PATENTS ARE DOMINANT OR SUBORDINATE TO THE PATENT RIGHTS. LICENSOR HAS NO OBLIGATION TO FURNISH TO LICENSEE ANY KNOW-HOW, TECHNOLOGY OR TECHNOLOGICAL INFORMATION.

 

	 
	
21

	

 

	 	
11.4

	
Licensee Representation

	 	
 

	
By execution of the Agreement, Licensee represents, acknowledges, covenants and agrees (a) that Licensee has not been induced in any way by Licensor or its employees to enter into the Agreement, and (b) that Licensee has been given an opportunity to conduct sufficient due diligence with respect to all items and issues pertaining to this Section 11 (Representations and Disclaimers) and all other matters pertaining to the Agreement; and (c) that Licensee has adequate knowledge and expertise, or has utilized knowledgeable and expert consultants, to adequately conduct the due diligence, and (c) that Licensee accepts all risks inherent herein. Licensee represents that it is a duly organized, validly existing entity of the form indicated in Section 1 of the Patent License Agreement, and is in good standing under the laws of its jurisdiction of organization as indicated in Section 1 of the Patent License Agreement, and has all necessary corporate or other appropriate power and authority to execute, deliver and perform its obligations hereunder.

 

	
12.

	
Limit of Liability

	
 

	 
	
 

	
IN NO EVENT SHALL LICENSOR, THE UNIVERSITY SYSTEM IT GOVERNS, ITS MEMBER INSTITUTIONS, INVENTORS, REGENTS, OFFICERS, EMPLOYEES, STUDENTS, AGENTS OR AFFILIATED ENTERPRISES, BE LIABLE FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL, INCIDENTAL, EXEMPLARY, OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR REVENUE) ARISING OUT OF OR IN CONNECTION WITH THE AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER ANY SUCH PARTY KNOWS OR SHOULD KNOW OF THE POSSIBILITY OF SUCH DAMAGES. OTHER THAN FOR CLAIMS AGAINST LICENSEE FOR INDEMNIFICATION (SECTION 13) OR FOR MISUSE OR MISAPPROPRIATION OR INFRINGEMENT OF LICENSOR’S INTELLECTUAL PROPERTY RIGHTS, LICENSEE WILL NOT BE LIABLE TO LICENSOR FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR REVENUE) ARISING OUT OF OR IN CONNECTION WITH THE AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER LICENSEE KNOWS OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES.

 

	
13.

	
Indemnification

 

	 	
13.1

	
Indemnification Obligation

	 	
 

	
Subject to Section 13.2, Licensee agrees to hold harmless, defend and indemnify Licensor, the university system it governs, its member institutions, its Regents, officers, employees, students and agents (“Indemnified Parties”) from and against any liabilities, damages, causes of action, suits, judgments, liens, penalties, fines, losses, costs and expenses (including, without limitation, reasonable attorneys’ fees and other expenses of litigation) (collectively “Liabilities”) resulting from claims or demands brought by third parties against an Indemnified Party on account of any injury or death of persons, damage to property, or any other damage or loss arising out of or in connection with the Agreement or the exercise or practice by or under authority of Licensee, its Affiliates or their Sublicensees, or third party wholesalers or distributors, or physicians, hospitals or other healthcare providers who purchase a Licensed Product, of the rights granted hereunder.

 

	 
	
22

	

 

	 	
13.2

	
Conditions of Indemnification

	 	
 

	
Licensee shall have no responsibility or obligation under Section 13.1 for any Liabilities to the extent caused by the gross negligence or willful misconduct by Licensor. Obligations to indemnify, and hold harmless under Section 13.1 shall not apply unless one or more of the Indemnified Parties: (a) promptly notifies Licensee of the claim or demand following receipt of written notice of such claim or demand; and (b) to the extent authorized by the Texas Constitution and the laws of the State of Texas, and subject to the statutory duties of the Texas Attorney General, gives Licensee control of the defense and settlement of the claim and demand; and (c) to the extent authorized by the Texas Constitution and the laws of the State of Texas and subject to statutory duties of the Texas Attorney General, the assistance reasonably , necessary in the defense and settlement,, at Licensee’s expense.

 

	
14.

	
Insurance

 

	 	
14.1

	
Insurance Requirements

	 	
 

	
Prior to any Licensed Product being used or Sold (including for the purpose of obtaining regulatory approvals), and prior to any Licensed Service being performed by Licensee, an Affiliate, or by a Sublicensee, and for a period of five years after the Agreement expires or is terminated, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in commercially reasonable and appropriate amounts for the Licensed Product being used or Sold or the Licensed Service being performed. Licensee shall use commercially reasonable efforts to have Licensor, the university system it governs, its member institutions, Regents, officers, employees, students, agents and inventors named as additional insureds. Such commercial general liability insurance shall provide, without limitation: (i) product liability coverage; (ii) broad form contractual liability coverage for Licensee’s indemnification under the Agreement; and (iii) coverage for litigation costs.

	 	
 

	 
	 	
14.2

	
Evidence of Insurance and Notice of Changes

	 	
 

	
Upon request by Licensor, Licensee shall provide Licensor with written evidence of such insurance. Additionally, Licensee shall provide Licensor with written notice of at least 60 days prior to Licensee cancelling, not renewing, or materially changing such insurance.

 

	
15.

	
Assignment

	
 

	
 

	
 

	
The Agreement may not be assigned by Licensee without the prior written consent of Licensor, which consent will not be unreasonably withheld. A merger or other transaction in which the equity holders of Licensee prior to such event hold less than a majority of the equity of the surviving or acquiring entity shall be considered an assignment of the Agreement. For any permitted assignment to be effective, (a) Licensee must be in good standing under this Agreement, (b) the Licensee must pay Licensor the assignment fee pursuant to Section 3.1(e), and (c) the assignee must assume in writing (a copy of which shall be promptly provided to Licensor) all of Licensee’s interests, rights, duties and obligations under the Agreement and agree to comply with all terms and conditions of the Agreement as if assignee were an original Party to the Agreement.

 

	
16.

	
Governmental Markings

 

	 	
16.1

	
Patent Markings

	 	
 

	
Licensee agrees that, to the extent reasonably feasible and consistent with practices that are common in the particular industry, all packaging containing individual Licensed Products, documentation therefor, and actual Licensed Products Sold by Licensee, Affiliates, or Sublicensees will be legibly marked with the number of any applicable patent(s) licensed hereunder as part of the Patent Rights in accordance with each country’s patent marking laws, including Title 35, U.S. Code.

 

	 
	
23

	

 

	 	
16.2

	
Governmental Approvals and Marketing of Licensed Products and or Licensed Services

	 	
 

	
Licensee will be responsible for obtaining all necessary governmental approvals for the development, production, distribution, Sale, and use of any Licensed Product or performance of any Licensed Service, at Licensee’s expense, including, without limitation, any safety studies. Licensee will have sole responsibility for any warning labels, packaging and instructions as to the use and the quality control for any Licensed Product or Licensed Service.

	 	
 

	 
	 	
16.3

	
Foreign Registration and Laws

	 	
 

	
Licensee agrees to register the Agreement with any foreign governmental agency that requires such registration; and Licensee will pay all costs and legal fees in connection with such registration. Licensee will assure that all foreign laws affecting the Agreement or the Sale of Licensed Products and Licensed Services are fully satisfied.

 

	
17.

	
Use of Name

	
 

	 
	
 

	
Licensee will not use the name, trademarks or other marks of Licensor (or the name of the university system it governs, its member institutions, any of its Regents or employees) in any advertising, promotional or sales literature, on its Web site or for the purpose of raising capital (except to provide factually based information about the Agreement while raising capital) without the advance written consent of Licensor. Licensor may use Licensee’s name and logo for annual reports, brochures, website and internal reports without prior consent.

	
 

	 
	
18.

	
Notices

	
 

	 
	
 

	
Any notice or other communication of the Parties required or permitted to be given or made under the Agreement will be in writing and will be deemed effective when sent in a manner that provides confirmation or acknowledgement of delivery and received at the address set forth in Section 18 of the Patent License Agreement (or as changed by written notice pursuant to this Section 18). Notices required under the Agreement may be delivered via E-mail provided such notice is confirmed in writing as indicated.

	
 

	 
	
 

	
Notices shall be provided to each Party as specified in the “Contact for Notice” address set forth in Section 18 of the Patent License Agreement. Each Party shall update the other Party in writing with any changes in such contact information.

	
 

	 
	
19.

	
General Provisions

 

	 	
19.1

	
Binding Effect

	 	
 

	
The Agreement is binding upon and inures to the benefit of the Parties hereto, their respective executors, administrators, heirs, permitted assigns, and permitted successors in interest.

	 	
 

	 
	 	
19.2

	
Construction of Agreement

	 	
 

	
Headings are included for convenience only and will not be used to construe the Agreement. The Parties acknowledge and agree that both Parties substantially participated in negotiating the provisions of the Agreement; therefore, both Parties agree that any ambiguity in the Agreement shall not be construed more favorably toward one Party than the other Party, regardless of which Party primarily drafted the Agreement.

 

	 
	
24

	

 

	 	
19.3

	
Counterparts and Signatures

	 	
 

	
The Agreement may be executed in multiple counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument. A Party may evidence its execution and delivery of the Agreement by transmission of a signed copy of the Agreement via facsimile or email. In such event, the Party shall promptly provide the original signature page(s) to the other Party.

	 	
 

	 
	 	
19.4

	
Compliance with Laws

	 	
 

	
Licensee will comply with all applicable federal, state and local laws and regulations, including, without limitation, all export laws and regulations.

	 	
 

	 
	 	
19.5

	
Governing Law

	 	
 

	
The Agreement will be construed and enforced in accordance with laws of the U.S. and the State of Texas, without regard to choice of law and conflicts of law principles.

	 	
 

	 
	 	
19.6

	
Modification

	 	
 

	
Any modification of the Agreement will be effective only if it is in writing and signed by duly authorized representatives of both Parties. No modification will be made by email communications.

	 	
 

	 
	 	
19.7

	
Severability

	 	
 

	
If any provision hereof is held to be invalid, illegal or unenforceable in any jurisdiction, the Parties hereto shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties, and all other provisions hereof shall remain in full force and effect in such jurisdiction and shall be construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such other provisions in any other jurisdiction, so long as the essential essence of the Agreement remains enforceable.

	 	
 

	 
	 	
19.8

	
Third Party Beneficiaries

	 	
 

	
Nothing in the Agreement, express or implied, is intended to confer any benefits, rights or remedies on any entity, other than the Parties and their permitted successors and assigns. However, if there is a joint owner of any Patent Rights identified in Section 1 of the Patent License Agreement (other than Licensee), then Licensee hereby agrees that the following provisions of these Terms and Conditions extend to the benefit of the co-owner identified therein (excluding the Licensee to the extent it is a co-owner) as if such co-owner was identified in each reference to the Licensor: the retained rights under clause (b) of Section 2.1; Section 11.3 (Licensor Disclaimers); Section 12 (Limitation of Liability); Section 13 (Indemnification); Section 14.1 (Insurance Requirements); Section 17 (Use of Name); and Section 19.10 (Sovereign Immunity, if applicable).

	 	
 

	 
	 	
19.9

	
Waiver

	 	
 

	
Neither Party will be deemed to have waived any of its rights under the Agreement unless the waiver is in writing and signed by such Party. No delay or omission of a Party in exercising or enforcing a right or remedy under the Agreement shall operate as a waiver thereof.

	 	
 

	 
	 	
19.10

	
Sovereign Immunity

	 	
 

	
Nothing in the Agreement shall be deemed or treated as any waiver of Licensor’s sovereign immunity.

 

	 
	
25

	

 

	 	
 

	 
	 	
19.11

	
Entire Agreement

	 	
 

	
The Agreement constitutes the entire Agreement between the Parties regarding the subject matter hereof, and supersedes all prior written or verbal agreements, representations and understandings relative to such matters.

	 	
 

	 
	 	
19.12

	
Claims Against Licensor for Breach of Agreement

	 	
 

	
Licensee acknowledges that any claim for breach of the Agreement asserted by Licensee against Licensor shall be subject to Chapter 2260 of the Texas Government Code and that the process provided therein shall be Licensee’s sole and exclusive process for seeking a remedy for any and all alleged breaches of the Agreement by Licensor or the State of Texas.

	 	
 

	 
	 	
19.13

	
Grant of Security Interest

	 	
 

	
Licensee hereby grants to Licensor a security interest in and to Licensee's rights under the Patent License Agreement, as collateral security for the payment by Licensee of any and all sums which may be owed from time to time by Licensee to Licensor. Licensor shall have all rights of a secured party as specified in the Texas Uniform Commercial Code relative to this security interest and the enforcement thereof. Licensee hereby authorizes Licensor to file with the appropriate governmental agencies appropriate UCC-1 financing statements to evidence this security interest.

 

-- END OF EXHIBIT A –

 

 

26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]